Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgarisReview Published on 2022-05-012023-07-06 Journal: The Journal of dermatological treatment [Category] COVID19(2023년), [키워드] COVID-19 pandemic rituximab SARS-CoV-2 [DOI] 10.1080/09546634.2020.1870648 [Article Type] Review
COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients천포창 환자의 COVID-19 중증도 및 SARS-Cov-2 백신 안전성Multicenter Study Published on 2022-05-012022-09-12 Journal: Dermatologic therapy [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] asked Autoimmune blistering Characteristics clinics collected Course COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 severity demographic data Dermatology died disease Diseases feature Hospitalization Immunosuppressant immunosuppressants investigated multicenter one patient outpatient clinic Patient patients pemphigus question required rituximab RTX SARS-CoV-2 System the disease Treatment Vaccine Vaccines [DOI] 10.1111/dth.15417 PMC 바로가기 [Article Type] Multicenter Study
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trialRandomized Controlled Trial Published on 2022-05-012023-07-07 Journal: Annals of the rheumatic diseases [Category] COVID19(2023년), [키워드] COVID-19 rituximab vaccination [DOI] 10.1136/annrheumdis-2021-221558 [Article Type] Randomized Controlled Trial
Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases전신 염증성 질환이 있는 면역 저하 환자에서 알파 및 델타 변이체에 대한 BNT162b2 백신의 면역원성Article Published on 2022-05-012022-09-11 Journal: Annals of the rheumatic diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] abrogated Alpha alpha and delta variants analysed anti-spike antibodies anti-spike antibody anti-Spike IgG B-cell B.1.617.2 BNT162b2 BNT162b2 vaccine Breakthrough infection breakthrough infections Control controls COVID-19 Delta delta variant Delta variants dose effort Endpoint evaluate exhibiting healthcare humoral Humoral response Immune escape immunocompromised individual immunocompromised individuals Immunocompromised patient Immunocompromised patients immunogenicity impairing IMPROVE individual infected with SARS-CoV-2 Inflammatory diseases Kinetics methotrexate mounted neutralisation neutralising Neutralising activity of BNT162b2 Other Patient primary endpoints Prospective raise regimen responses rituximab SARS-CoV-2 secondary Secondary endpoints sera Seroconversion Specific T-cell response strain Strains Support systemic inflammatory disease systemic inflammatory diseases T-cell T-cell Response T-cell responses therapeutic treated vaccination Vaccine Viral viral fitness [DOI] 10.1136/annrheumdis-2021-221508 PMC 바로가기 [Article Type] Article
T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients장기 리툭시맙 치료 환자에서 Sars-Cov2 BNT162b2 Pfizer 백신 3회 투여에 대한 T 세포 반응Article Published on 2022-05-012022-09-12 Journal: European journal of internal medicine [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Abstract BNT162b2 Pfizer vaccine dose rituximab SARS Cov2 vaccine T-cell Response T-cells treated patient [DOI] 10.1016/j.ejim.2022.01.030 PMC 바로가기 [Article Type] Article
Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses리툭시맙으로 치료받은 자가면역 질환 환자와 2회 접종에 무반응자에서 세 번째 COVID-19 백신 접종 후 체액 반응 비율이 매우 낮음Article Published on 2022-05-012022-09-12 Journal: RMD Open [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Abstract Arthritis, Rheumatoid Autoimmune disease Autoimmune diseases COVID-19 COVID-19 vaccine dose humoral non-responder Patient rituximab treated vaccination [DOI] 10.1136/rmdopen-2022-002308 PMC 바로가기 [Article Type] Article
Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination백신에 불응하는 자가면역 류마티스 질환이 있는 B 세포 고갈 환자에서 SARS-CoV-2에 대한 전신 및 점막 면역에 대한 카시리비맙/임데비맙의 효과Article Published on 2022-05-012022-09-12 Journal: RMD Open [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Abstract Autoimmune Autoimmune diseases B-cell COVID-19 Effect Epidemiology Immunity mucosal Patient rheumatic disease rituximab SARS-CoV-2 vaccination [DOI] 10.1136/rmdopen-2022-002323 PMC 바로가기 [Article Type] Article
Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases완전 관해 B-세포 림프종 및 항-CD20 단일클론항체 치료를 받은 중증 면역저하 환자에서 SARS-CoV-2 감염 지속: 2건의 증례 보고Randomized Controlled Trial Published on 2022-04-142022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] acute infection acute respiratory syndrome anti-CD20 B-cell lymphoma Case report condition coronavirus coronavirus disease Corticosteroids COVID-19 described Evidence Hematological malignancy Hyperimmune plasma Immunocompromised Immunosuppressant Infection information lymphoid lymphoma malignancy Nasopharyngeal swab Patient plasma positive Randomized controlled trials receiving Remdesivir Remission report risk rituximab RT-PCR SARS-CoV-2 subgroup of patient susceptible therapy treated Treatment viral replication [DOI] 10.3389/fimmu.2022.860891 PMC 바로가기 [Article Type] Randomized Controlled Trial
Case Report: Acquired Haemophilia A Following mRNA-1273 Booster Vaccination Against SARS-CoV-2 With Concurrent Diagnosis of Pleomorphic Dermal Sarcoma증례 보고서: 다형성 피부 육종의 동시 진단과 함께 SARS-CoV-2에 대한 mRNA-1273 추가 백신 접종 후 획득한 혈우병 ACase Reports Published on 2022-04-112022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, [키워드] Acquired acquired haemophilia A acute respiratory syndrome acute respiratory syndrome coronavirus adverse event Against AHA approved association Autoimmune Blood blood clotting booster booster vaccination Care causal relationship caused characterized clotting factor VIII concurrent coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Cyclophosphamide Dermal Diagnosis diagnostic tests Escalation event factor VIII factor VIII autoantibodies Follow-up forehead FVIII global pandemic Glucocorticoids haemophilia herd immunity Immunity Immunosuppression Immunosuppressive treatment individual information inhibitor malignancy malignant disease mRNA mRNA-1273 mRNA-1273 booster new virus occurred pandemic patients Pleomorphic pleomorphic dermal sarcoma. Post-marketing surveillance PROTECT rare events recorded reported rituximab RTX Sarcoma SARS-CoV-2 SARS-CoV-2 vaccination severe complication severe complications Surveillance the patient Treatment Trigger triggered vaccination Vaccinations Vaccine Vaccines variant while [DOI] 10.3389/fimmu.2022.868133 PMC 바로가기 [Article Type] Case Reports
Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab리툭시맙 치료 후 지속적인 감염에서 SARS-CoV-2의 바이러스 진화 및 면역학Case Reports Published on 2022-04-032022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] accelerated accumulated accumulation Asymptomatic clade Clinical course clinical implications Community Complete Complete Remission Ct-value Culture Deletion deletions demonstrated described facilitate growth hospitalised Immunocompromised Immunocompromised host immunocompromised individual immunocompromised individuals Immunocompromised patient Immunocompromised patients immunologic response immunosuppressive immunosuppressive therapy increase in individuals Infection prevention lymphocyte Lymphocyte count lymphoma measure Mutation N-terminal domain Nasopharyngeal swab Patient persistence persistent persistent infection positive Prolonged qPCR remained rituximab RT-qPCR SARS-CoV-2 SARS-CoV-2 genome Spike protein Spread the SARS-CoV-2 genome therapy variants variants of concern variants of concern (VOC) Viral viral evolution virus VoC WGS whole genome Whole genome sequencing wildtype [DOI] 10.3390/v14040752 PMC 바로가기 [Article Type] Case Reports